P-mapa, a promisor immunomodulator against tumor cells of colonic tissues: An investigation of the action mechanism over the TLR4 signaling pathway

Socca, Eduardo Augusto Rabelo; Reis, Sabrina Karen; Genaro, Sandra Cristina; Reis, Ianny Brum; Böckelmann, Petra Karla; Fávaro, Wagner José

doi:10.1016/j.lfs.2019.117185

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these studies, compounds that are capable of acting as Toll-like receptor agonists (TLRs) can be evaluated and developed as anticancer drugs (10). The Protein aggregate magnesium-ammonium phospholinoleatepalmitoleate anhydride (P-MAPA) acts as an agonist for TLRs 2 and 4, as well as activates p53, promoting tumor regression in NMIBC, suppressing abnormal cell proliferation and preventing tumor expansion [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Effects of P-MAPA as Immunomodulator on Markers for Energy Metabolism in Bladder Cancer

Fávaro¹,

Böckelmann²,

García³

et al. 2020

ann urol oncol

View full text Add to dashboard Cite

Introduction This study characterized and compared cellular energetic metabolism features in the treatment of chemically induced non-muscle invasive bladder cancer (NMIBC) in Fischer 344 rats that were submitted to intravesical immunotherapies with P-MAPA (Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride) and Bacillus Calmette-Guérin (BCG). Methods Rat urinary bladder samples from Control, NMIBC (Cancer), NMIBC+BCG and NMIBC+P-MAPA groups were submitted to histopathological and western blotting analyses for the following proteins: GLUT 1, PFK, GAPDH, HADHSC, β-F1-ATPase, AMPK and mTOR. Results P-MAPA Intravesical treatment was effective in tumor regression and histologic recovery of the urinary bladder in the NMIBC. There was a significant increase in protein levels of GLUT 1, mTOR, GAPDH and HADHSC in the NMIBC+P-MAPA group. It was observed an increase in protein levels of PFK and β-F1-ATPase and a significant reduction in protein levels of AMPk in the NMIBC group. Conclusions Our results showed that immunotherapy with P-MAPA may be an alternative in the treatment of NMIBC, especially in cases where BCG therapy failure, as evidenced by the effect of P-MAPA on tumor regression.

show abstract

Section: Introductionmentioning

confidence: 99%